NeuroOne filed its FDA 510(k) for trigeminal nerve ablation months ahead of its revised May 2025 timeline. OneRF system targets trigeminal neuralgia, a condition impacting ~100K in the U.S., using ...

During surgery, veins combined with arachnoid adhesions and arachnoid adhesions alone were observed compressing the trigeminal nerve in seven patients (17.50%) and 33 patients (82.50%), respectively.

In migraine, the trigeminal nerve plays a crucial role. It transmits pain signals from the brain to the face, where flare-ups occur. Migraine causes severe headaches with other symptoms like ...

During surgery, veins combined with arachnoid adhesions and arachnoid adhesions alone were observed compressing the trigeminal nerve in seven patients (17.50%) and 33 patients (82.50%), respectively.

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) filed its 510(k) submission to the FDA for trigeminal nerve ablation on Wednesday, earlier than previously guided. NeuroOne Medical is ...

has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.

(RTTNews) - NeuroOne Medical Technologies Corp. (NMTC) on Wednesday announced that it has completed its 510(k) submission to the U.S. Food and Drug Administration for its OneRF Trigeminal Nerve ...

NeuroOne Medical Technologies has submitted its 510(k) filing to the FDA for a new treatment option for trigeminal neuralgia earlier than anticipated, indicating efficient progress in product ...

"If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025.” NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is ...

This submission leverages the Company's proprietary OneRF ® Ablation System RF generator platform for the treatment of trigeminal neuralgia, a chronic pain condition affecting approximately ...